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Abstract
Due to the frequent contribution in the pathogenesis of different human malignancies, c-Myc 
is among those transcription factors that are believed to be pharmacologically targeted for cancer 
therapeutic approaches. In the present study, we examined the anti-leukemic effect of a well-known 
c-Myc inhibitor 10058-F4 on a panel of hematologic malignant cells harboring either mutant or 
wild-type p53. Notably, we found that the suppression of c-Myc was coupled with the reduction in 
the survival of all the tested leukemic cells; however, as far as we are aware, this study suggests for 
the first time that the cytotoxic effect of 10058-F4 was not significantly affected by the molecular 
status of p53. Delving into the molecular mechanisms of the inhibitor in the most sensitive cell 
line revealed that 10058-F4 could induce apoptotic cell death in mutant p53-expressing NB4 cells 
through the suppression of NF-κB pathway coupled with a significant induction of intracellular 
reactive oxygen species (ROS). In addition, we found that the anti-leukemic effect of 10058-F4 was 
overshadowed, at least partially, through the compensatory activation of the PI3K signaling pathway; 
highlighting a plausible attenuating role of this axis on 10058-F4 cytotoxicity. In conclusion, the 
results of the present study shed light on the favorable anti-leukemic effect of 10058-F4, especially in 
combination with PI3K inhibitors in acute promyelocytic leukemia; however, further investigations 
should be accomplished to determine the efficacy of the inhibitor, either as a single agent or in a 
combined-modal strategy, in leukemia treatment. 
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Introduction
Upon the first description of MYC gene 
in the human genome, it was believed that 
this protein only serves as a transcription 
factor (1, 2). However, as the biological 
characteristics became clearer, it has been 
suggested that c-Myc plays a key role in the 
regulation of more biological disciplines, 
including cell proliferation, cell metabolism, 
and cell survival (3). As its role in tumor 
progression emerges, numerous studies have 
peered into the therapeutic ability of this onco-
protein, either as a prognostic biomarker or 
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as an appealing target for cancer treatment. 
In a study conducted by Nalan et al., it was 
reported that rearrangement of c-Myc in 
diffuse large B cell lymphoma (DLBCL) could 
be an effective biomarker to predict high risk 
patients (4). In another study, it has also been 
indicated that over-expression of c-Myc could 
alter the expression level of apoptosis-related 
genes, playing a key role in the development 
of mantle cell lymphoma (5). The association 
between c-Myc overexpression and the 
incidence of human hematologic malignancies, 
in particular acute leukemia, has also been 
well-established in numerous studies (6, 7). 
Being the most deregulated proto-oncogene in 
hematologic malignances, it has been reported 
that aberrant c-Myc expression is frequently 
associated with poor prognosis (8).
Owing to the aberrant expression of c-Myc, 
numerous attempts have been launched to 
identify pharmacologic inhibitors of c-Myc 
for therapeutic applications. Computer-aided 
drug discoveries have lately laid a foundation 
for developing potent and clinically optimized 
c-Myc inhibitors that could serve as favorable 
therapeutics (9). Given to its favorable anti-
cancer property, 10058-F4 is among those 
c-Myc inhibitors that are believed to bring 
advantages for the treatment of various types of 
cancers, especially in the term of combination 
therapy. The remarkable anti-cancer property 
of this inhibitor has been reported in different 
solid tumors including ovarian cancer (10), 
hepatocellular carcinoma (11), prostate cancer 
(9), and hypopharyngeal carcinoma (12), 
as well as hematologic malignancies (13, 
14). In a more recent investigations, it was 
also delineated that co-targeting c-Myc and 
other components of signaling pathways, for 
instance PI3K (15), PAK (16), and ERK (17) 
may be more efficient in reducing the number 
of cancer cells in human malignancies. 
Moreover, it has been suggested that the 
suppression of c-Myc could be a promising 
strategy to enhance the anti-leukemic property 
of vincristine, a potent chemotherapeutic 
drug used in the first line treatment of acute 
lymphoblastic leukemia (14, 18). Although 
the anti-tumor effects of the inhibitor has 
turned into an area of focus in the recent years, 
the underlying molecular mechanisms through 
which 10058-F4 exerts its favorable effects has 
not yet been described properly. To the best of 
our knowledge, to date, no study has addressed 
the potential role of p53 status in leukemic 
cell response to 10058-F4 and this study 
suggested for the first time that the favorable 
cytotoxic effect of 10058-F4 in leukemic cells 
could not be swayed by the molecular status 
of p53. We found that the superior cytotoxic 
effect of this agent in 53-mutant expressing 
NB4 cells, as the most sensitive cell line, is 
mediated probably through NF-κB-mediated 
augmentation reactive oxygen species (ROS) 
level.
Experimental
Cell culture and drug treatment
To investigate the effects of 10058-F4 on 
hematologic malignant cell lines, a panel of 
cells consists of U937, Nalm-6, REH, KG-1, 
KMM-1, HL-60, and NB4 (Pasteur Institute, 
Tehran, Iran) cells were grown in RPMI 
1640 medium supplemented with antibiotics, 
10% fetal bovine serum (Invitrogen) and 2 
mM l-glutamine (Invitrogen) in the presence 
of 5% CO2 at 37 °C. The relevant amount 
of 10058-F4 was dissolved in sterile PBS 
to make a stock solution. Moreover, PI3K 
inhibitor CAL-101 (Selleckchem, Munich, 
Germany), proteasome inhibitor Carfilzomib 
(Selleckchem, Munich, Germany), and 
autophagy inhibitor chloroquine (CQ) (Sigma, 
Taufkirchen, Germany) were prepared, divided 
to aliquots, and stored at −20 °C until use.
Trypan blue assay test of cell count and 
viability
To assess the suppressive effect of 10058-
F4 on the viability and growth kinetics, 
hematologic malignant cell lines were 
incubated with designated concentrations of 
c-Myc inhibitor, either alone or in combination 
with several anti-cancer agents. After indicated 
treatment intervals, the drug-treated cells 
were mixed with 0.4% trypan blue solution 
(Invitrogen) in a 1:1 ratio and then the mixture 
was allowed to incubate for 1–2 min at room 
temperature and loaded onto the chamber of 
Neubauer hemocytometer. The total number 
of unstained (viable) and the stained (non-
viable) cells were manually counted and the 
percentage of viable cells was calculated.
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Detection of metabolic activity by micro-
culture tetrazolium test
To assess whether the treatment of the cells 
10058-F4, as a single agent or in combined 
modality, could reduce the metabolic activity, 
the hematologic malignant cells were treated 
with different concentrations of this c-Myc 
inhibitor, either alone or in combination with 
other anti-leukemic agents. After treatment of 
the cells with different agents, we incubated 
the cells with 100 μL of MTT solution for 
a further 3 h in a humidified incubator. The 
optical densitometry of a resulting formazan 
solubilized with DMSO was measured in an 
enzyme-linked immunosorbent assay (ELISA) 
reader at the wavelength of 570 nm. The 
percentage of metabolic activity was calculated 
as (%) = (ODexp/ODcon) × 100; where ODexp and 
ODcon are the optical densities of exposed and 
control cells, respectively.
BrdU cell proliferation assay
The suppressive effect of 10058-F4 on the 
growth and proliferation of NB4 cells was 
assessed by measuring DNA synthesis rate of the 
cells using a colorimetric bromodeoxyuridine 
(BrdU)-based cell proliferation ELISA 
kit (Roche, Penzberg, Germany) as per 
manufacturer’s recommendations. Initially, 
APL-derived cells were seeded into 96-
well plate at a density of 5000 cells/well and 
treated with the desired concentrations of 
10058-F4. Afterwards, 10 μL/well of BrdU 
labeling solution was added, and the cells 
were re-incubated at 37 °C for 12 h. Then, the 
cells were then fixed and DNA was denatured 
using 200 μL of FixDenat solution provided 
with the kit. After 30 min and discarding 
Fixodent, 100 μL peroxidase-conjugated anti-
BrdU (antiBrdU-POD) antibody was added 
to each well. Finally, the cells were incubated 
with tetramethylbenzidine (TMB) for 3 min at 
room temperature and the reaction product was 
quantified by measuring the absorbance at 450 
nm.
Cell cycle distribution analysis
The impact of 10058-F4 on the distribution 
of the cells in the different phases of the cell 
cycle were ascertained by flow cytometric 
analysis after 24 h incubation of NB4 cells with 
different concentrations of the inhibitor. In brief, 
1 × 106 cells were harvested, washed twice with 
cold PBS, and then fixed in 70% ethanol. Next, 
propidium iodide (PI) and RNase were used 
to stain DNA and degrade RNA, respectively. 
DNA content of the cells was quantified from 
the peak analysis of flowcytometric histograms, 
and the data were interpreted using the Windows 
FlowJo™ v10 software.
Assessment of apoptosis using flow 
cytometry
The apoptotic effect of 10058-F4, either 
alone or in combination with CAL-101 against 
APL-derived cells were investigated by 
Annexin-PI staining assay. Briefly, the cells 
were harvested after 24 h of treatment with 
the designated concentrations of the inhibitor, 
washed with PBS, and re-suspended in a total 
volume of 100 μL of the incubation buffer at 
a concentration of 1 × 106 cells/mL. After that, 
Annexin-V-Flous (2 μL per sample) was added, 
and the cell suspensions were incubated for 20 
min in the dark. After incubation, Fluorescence 
was quantified using flow cytometry.
Measurement of caspase-3 enzymatic 
activity
To determine whether 10058-F4-induced 
apoptosis is mediated through caspase-
dependent cascade, we investigated the 
enzymatic activity of caspase-3 using a 
caspase-3 assay kit (Sigma). Briefly, the cells 
were treated with 100, 150, and 200 μM 
10058-F4 and incubated at 37 °C for 24 h. 
Following centrifugation at 600 ×g for 5 min, 
the cell pellets were lysed and the lysates were 
centrifuged at 20,000 ×g for 10 min. In a total 
volume of 100 μL, 5 μg of the supernatant was 
incubated with 85 μL of assay buffer plus 10 μL 
of caspase-3 substrate in a 96-well plate at 37 
°C. The cleavage of the peptide by caspase-3 
released the chromophore pNA, which was 
quantified spectrophotometrically at 405 nm.
Western blot analysis
NB4 cells were centrifuged after treatment 
with 100 and 150 µM of 10058-F4, and the 
cellular pellets were lysed in RIPA buffer 
containing protease and phosphatase inhibitor 
cocktails (Sigma). The protein concentration 
was determined according to Bradford method 
and then equivalent amounts of total cellular 
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protein were separated by 10% SDS-PAGE, 
and subsequently transferred to nitrocellulose 
membrane using a semidry transfer cell 
(Bio-Rad). Afterwards, the membranes were 
blocked with 5% non-fat dry milk in TBS 
containing 0.1% (v/v) Tween-20 for 1 h at room 
temperature. The proteins were detected using 
specific primary antibodies against IκB, p- IκB, 
Akt, p-Akt, cleaved PARP, β-actin, cleaved 
PARP (cell signaling), and cleaved caspase-3 
(Abcam), and the enhanced chemiluminescence 
detection system according to the manufacturers 
protocol.
RNA extraction and cDNA synthesis
Total RNA from 10058-F4-treated cells 
was extracted using RNA Isolation Kit (Roche, 
Mannheim, Germany) and quantified by 
Nanodrop instrument. The reverse transcription 
reaction was performed using Complementary 
DNA (cDNA) Synthesis Kit (Takara Bio, 
Shiga, Japan). Adapted times and temperature 
profiles for the reverse transcription were used: 
incubation for 5 min at 65 °C, 5 min at 25 °C, 
followed by 60 min at 42 °C. The reaction was 
terminated by heating for 5 min at 70 °C.
Quantitative real-time PCR
Changes in mRNA expression level of 
the desired genes were assessed by real-time 
PCR that was performed with a light cycler 
instrument (Roche Diagnostics, Germany) 
using SYBR Premix Ex Taq technology 
(Takara Bio, Inc.). For this purpose, PCR assay 
was performed in an ultimate volume of 20 μL 
of reaction mixture containing 10 μL of SYBR 
Green master mix, 2 μL of cDNA product, 
0.5 μL of each forward and reverse primers 
(10 pmol) and 7 μL of nuclease-free water 
(Qiagen, Hilden, Germany). Thermal cycling 
conditions included an initial activation 
step for 30 s at 95 °C followed by 40 cycles 
including a denaturation step for 5s at 95 °C 
and a combined annealing/extension step for 
20 s at 60 °C. Melting curves were analyzed to 
verify single PCR product of each primer ABL 
housekeeping gene amplified as an internal 
control, and fold change in the expression 
of each target mRNA relative to ABL was 
calculated on the basis of a comparative on 
2-ΔΔct relative expression formula.
Intracellular reactive oxygen species 
detection
To determine the effect of 10058-F4 on the 
amount of intracellular reactive oxygen species 
(ROS) in NB4 cells, we used a fluorogenic dye 
DCFH-DA, for measuring hydroxyl, peroxyl 
and other ROS activity within the cell. After 
incubation with the desired concentrations of 
the nanocomposite, the cells were incubated 
with DCFH-DA at 37 °C for 30 min. Finally, 
fluorescence intensities of the samples were 
detected by fluorescence spectrophotometer 
(Cary Eclipse, USA) with excitation at 485 nm 
and emission at 530 nm.
Statistical analysis
Experimental data were evaluated in 
triplicate against untreated control cells and 
collected from three independent experiments. 
The significance of differences between 
experimental variables was determined by 
the use of two tailed student’s test. In order to 
compare between the control group and the 
treated ones, the Dunnett’s multiple comparison 
test was used. All data are presented as mean 
± standard deviation (SD) and a probability 
level of P ≤ 0.05 was considered statistically 
significant.
Results
Abrogation of c-Myc using 10058-F4 
reduced survival of hematologic malignant cell 
lines
Not so long time after the discovery of the 
fundamental role of c-Myc in immortalization 
of malignant cells in different human cancers, 
the specific small molecule inhibitors of this 
factor have found their way in the route of 
targeted therapies (19). Our results in a panel of 
leukemic cells showed that not only 10058-F4 
could decrease c-Myc expression level (Figure 
1). We also found that c-Myc suppression 
using 10058-F4 potently decreased viability, 
cell count and metabolic activity of all the cell 
lines; however, the IC50 values varied among 
the tested cells (Figure 2). Ample genetic and 
laboratory studies suggest that the promoter 
of c-Myc has a binding site for p53 tumor 
suppressor protein (20). Given this, it was 
attractive to examine whether the difference in 
157
NF-κB-dependent Mechanism of -Myc inhibitor 10058-F4 in APL cells
the sensitivity pattern of the cells to 10058-F4 
could be as a results of the molecular status of 
p53. Based on our supplemental investigations 
on a panel of hematologic malignant cell lines, 
we failed to identify any significant linking 
between molecular status of p53 and cell 
response to 10058-F4 (Figure 3), indicating the 
potential application of the inhibitor either in 
wild-type or deficient p53-expressing leukemic 
cells.
10058-F4 reduced NB4 cell viability 
through induction of a caspase-3-dependent 
apoptosis
To precisely delve into the underlying 
mechanisms responsible for the anti-leukemic 
effect of 10058-F4 on the most sensitive cell 
line, we chose APL-derived NB4 cells for 
further experiments. In agreement with the 
results of trypan blue and MTT assays, FACS 
analysis of Annexin-V/PI staining revealed that 
 
 
Figure 2. Inhibitory effect of 10058-F4 on viability, cell count, and metabolic activity of leukemic cell lines. 10058-
F4 induced anti-leukemic effect in all cell lines; however, a different cell sensitivity pattern was noted among the 
tested cells. Values are given as mean ± standard deviation of three independent experiments. *P ≤ 0.05 represented 
significant changes from the control. 
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leukemic effect in all cell lines; however, a different cell sensitivity pattern was noted among the tested cells. Values are given as mean 
± standard deviation of three independent experiments. *P ≤ 0.05 represented significant changes from the control.
 
Figure 1. The effect of 10058-F4 on the expression level of c-Myc. After exposing the panel of hematologic 
malignant cell lines with 10058-F4 at the concentrations of 100 and 200 µM, the mRNA expression level of c-Myc 
was evaluated. Values are given as mean ± standard deviation of three independent experiments. *P ≤ 0.05 
represented significant changes from the control. 
  
Figure 1. The effect of 10058-F4 on the expression level of c-Myc. After exposing the panel of hematologic malignant cell lines with 
10058-F4 at the concentrations of 100 and 200 µM, the mRNA expression level of c-Myc was evaluated. Values are given as mean ± 
standard deviation of three independent experiments. *P ≤ 0.05 represented significant changes from the control.
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the treatment of NB4 cells with c-Myc inhibitor 
led to a considerable increase in Annexin-V/
PI double positive cells (Figure 4A). Induction 
of apoptosis in NB4 was also authenticated 
by western blot and caspase-3 activity assays, 
which disclosed that the apoptotic cell death is 
primarily due to the induction of a caspase-3-
mediated apoptosis in NB4 cells. As presented 
in Figure 4B, we found that 10058-F4 increased 
the amount of cleaved PARP and caspase-3 
and up-regulated the enzymatic activity of this 
enzyme in a concentration-dependent manner.
The anti-leukemic effect of 10058-F4 on 
NB4 cells is mediated through suppression of 
NF-κB pathway
From the first description of c-Myc in 
leukemogenesis, its tight association with the 
NF-κB signaling pathway has been investigated 
in several reports (21), hinting this point that 
the anti-leukemic effect of c-Myc inhibition 
may be mediated through modulation of NF-
κB. Of note, the results of western blot analysis 
revealed that 10058-F4 potently reduced both 
the expression and phosphorylation level of 
IκB in NB4 cells (Figure 5A). Accordingly, 
we found that the suppression of NF-κB axis 
using a well-known proteasome inhibitor 
carfilzomib (CFZ) enhanced the ability of 
10058-F4 to reduce survival and proliferation 
capacity of NB4; shedding more light on the 
contributory role of NF-κB pathway on the 
mechanism of action of 10058-F4 (Figure 5B). 
The results of qRT-PCR analysis also revealed 
that combination of 10058-F4 with carfilzomib 
remarkably reduced the survival of NB4 cells 
through alteration in the expression level of 
both anti- and pro-apoptotic-related genes 
(Figure 5C).
10058-F4 impeded proliferation of NB4 
through ROS-mediated alteration of cell cycle
Based on the suppressive effect of 10058-
F4 on NF-κB signaling pathway and given to 
 
 
Figure 3. The anti-leukemic effect of 10058-F4 on hematologic malignant cell lines is exerted irrespective of the 
molecular status of p53. Based on our supplemental investigation and an extensive literature review, a list of IC50 
response of different leukemic cell lines to 10058-F4 after 24 h was made. IC50 of starred cell lines was evaluated in 
our laboratory. Dot blot showing correlation between p53 status and in-vitro drug sensitivity as shown by the IC50 of 
individual cell line. Lines indicate median value. We failed to identify an obvious association between p53 status 
and leukemic cell sensitivity to 10058-F4. Values are given as mean ± standard deviation of three independent 
experiments. 
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p53. Based on our supplemental investigation and an extensive literature review, a list of IC50 response of different leukemic cell lines 
to 10058-F4 after 24 h was made. IC50 of starred cell lines was evaluated in our laboratory. Dot blot showing correlation between p53 
status and in-vitro drug sensitivity as shown by the IC50 of individual cell line. Lines indicate median value. We failed to identify an 
obvious association between p53 status and leukemic cell sensitivity to 10058-F4. Values are given as mean ± standard deviation of 
three independent experiments.
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Figure 4. Abrogation of c-Myc induced caspase‐3‐dependent apoptosis in NB4 cell lines. (A) Treatment of NB4 
cells with 10058-F4 remarkably increased the percentages of Annexin-V/PI positive cells. (B) 10058-F4 imposed a 
considerable elevation in caspase-3 activity and increased the amount of cleaved caspase 3 and PAPR. Values are 
given as mean ± SD of three independent experiments. *P ≤ 0.05 represented significant changes from the control. 
  
Figure 4. Abrogation of c-Myc induced caspase‐3‐dependent apoptosis in NB4 cell lines. (A) Treatment of NB4 cells with 10058-F4 
remarkably increased the percentages of Annexin-V/PI positive cells. (B) 10058-F4 imposed a considerable elevation in caspase-3 
activity and increased the amount of cleaved caspase 3 and PAPR. Values are given as mean ± SD of three independent experiments. 
*P ≤ 0.05 represented significant changes from the control.
Figure 5. The anti-leukemic effect of 10058-F4 is mediated through suppression of NF-κB and its associated genes. (A) After the 
treatment of cells with the indicated concentrations of 10058-F4 for 24 h, total cell lysates were prepared and western blotting was 
performed using antibodies specific to IκB, p-IκB and Actin. (B) Suppression of proteasome using carfilzomib (CFZ) potentiate 
the anti-leukemic effect of 10058-F4. (C) The results of qRT-PCR analysis revealed that expression of both pro- and anti-apoptotic 
target genes altered more significantly when 10058-F4 was used in combination with CFZ. Values are given as mean ± SD of three 
independent experiments. *P ≤ 0.05 represented significant changes from the control.
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the penetrance of this axis on the generation 
of intracellular reactive oxygen species (ROS) 
(22), we aimed to examine whether there 
was a correlation between c-Myc inhibition 
and ROS production in NB4. Our results 
showed that 10058-F4 remarkably augmented 
the intracellular level of ROS in inhibitor-
treated cells in a concentration-dependent 
manner (Figure 6A). It has been reported that 
activation of ROS in cancer cells could impaire 
the replication of DNA in S phase of cell 
cycle making malignant cells more vulnerable 
to the death stimuli (23). In agreement with 
the elevation of ROS, DNA content analysis 
revealed that 10058-F4 potently reduced the 
percentage of NB4 cells in S phase of cell 
cycle (Figure 6B). This finding was further 
straighten out with BrdU incorporation 
assay indicating that there is a concentration-
dependent reduction in the DNA synthesis 
rate of NB4 cells after exposure to 10058-F4 
(Figure 6C). Moreover, cell cycle analysis by 
flow cytometry revealed that the percentage 
of hypodiploid cells, which are detected by 
so-called sub-G1 peak, significantly elevated 
which is in agreement with the results of 
Annexin-PI staining assay.
The attenuating effect of autophagy on the 
anti-leukemic effect of 10058-F4 in NB4 cells
Acting in contrast to ROS, activation of 
autophagy system in malignant cells has been 
reported to aid tumor cells to survive for the 
longer period of time (24). We found that 
10058-F4 potently suppressed the induction of 
autophagy through down-regulation of genes 
involved in the formation of autophagosome 
(Figure 6D). Moreover, our results showed 
that when autophagy system was inhibited in 
NB4 cells using the non-toxic concentration 
of chloroquine, the anti-leukemic property of 
10058-F4 was enhanced more significantly 
(Figure 6D), suggestive of the attenuating role 
of autophagy on the cytotoxicity of the inhibitor. 
Playing in a triangle, the tight correlation between 
the autophagy system, the PI3K signaling 
pathway, and c-Myc has been investigated in 
several studies (25, 26). Noteworthy, when 
 
Figure 6. Effect of 10058-F4 on ROS level, the cell cycle progression and autophagy system. (A) Upon treatment of 
NB4 cells with 1008-F4, the intercellular level of ROS was elevated in a concentrations-dependent manner. (B) 
Treatment of the cells with 10058-F4 increased the proportion of NB4 cells in sub-G1 phase, while there was a 
reduction in the percentage of cells S phase. (C) The results of BrdU assay showed that 10058‐F4 could hamper the 
replicative potential of APL cells through reducing DNA synthesis rate. (D) The single agent of 10058-F4 could 
remarkably diminished the expression level of autophagy-related genes in NB4 cells. Moreover, when autophagy 
system was suppressed using chloroquine, the cytotoxic effect of 10058-F4 was remarkably reinforced. Values are 
given as mean ± SD of three independent experiments. *P ≤ 0.05 represented significant changes from the control. 
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we examined the effect of 10058-F4 on the 
PI3K signaling pathway, we found that the 
amount of phosphorylated Akt, as the most 
critical component of the PI3K pathway, was 
elevated in response to the inhibitor which 
could be probably due to the malignant 
cells desire for longer survival (Figure 7). In 
agreement, co-treatment with PI3K inhibitor 
CAL-101 and c-Myc inhibitor 10058-F4 
remarkably diminished the survival capacity 
of NB4 cells (Figure 7), which may explain, 
at least partially, the compensatory role of the 
PI3K pathway upon c-Myc suppression. This 
finding was then substantiated by the results 
of Annexin-V staining assay which revealed 
that the proportion of apoptotic cells elevated 
dramatically when NB4 cells were exposed to 
both c-Myc and PI3K inhibitors (Figure 7).
 
Figure 7. The effect of 10058-F4 on the PI3K signaling pathway. The results of western blot analyzing revealed that 
upon c-Myc inhibition the amount of phosphorylated Akt increased in NB4 cells. When 10058-F4 was accompanied 
by a PI3K inhibitor, CAL-101, the survival of NB4 cells were decreased more efficiently as compared to either 
agents alone. Values are given as mean ± SD of three independent experiments. *P ≤ 0.05 represented significant 
changes from the control. 
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inhibition the amount of phosphorylated Akt increased in NB4 cells. When 10058-F4 was accompanied by a PI3K inhibitor, CAL-101, 
the survival of NB4 cells were decreased more efficiently as compared to either agents alone. Values are given as mean ± SD of three 
independent experiments. *P ≤ 0.05 represented significant changes from the control.
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Discussion
Soon after the discovery of MYC family 
genes and their involvement in oncogenic 
processes spanning from the regulation of 
cell growth to the maintenance of cancer cell 
survival, it was postulated that c-Myc inhibition 
could be translated into therapeutic approaches 
(8). The results obtained from the present 
study outlined that abrogation of c-Myc using 
novel specific inhibitor 10058-F4 remarkably 
reduced the survival and proliferative capacity 
of a panel of acute leukemia cell lines 
harboring an overexpressed c-Myc; however, 
a different cell sensitivity pattern was noted 
in response to the inhibitor. Given to the fact 
that c-Myc has a binding site on its promotor 
for p53 and its expression could be affected 
by the activity of this tumor suppressor (20), 
it was reasonable to hypothesize that the 
molecular status of p53 may influence on the 
extent of cell response to 10058-F4. Notably, 
our supplementary experiments revealed that 
there was no significant correlation between 
molecular status of p53 and leukemic cell 
response, which was in agreement with a 
previous disclosure which also failed to 
find any differential sensitivity pattern with 
respect to PTEN status (13). Taken together, 
it is assumed that the anti-leukemic effect of 
10058-F4 is probably mediated regardless 
of the molecular status of PTEN and p53; 
highlighting the efficacy of this inhibitor in 
either wild-type or mutan PTEN and/or p53 
leukemic cells.
The favorable anti-leukemic effect of the 
inhibitor on the most sensitive cell line was 
substantiated by apoptosis analysis, where we 
found that the lower concentrations of 10058-
F4 induced a caspase-3-dependent apoptosis 
in APL-derived NB4 cells. It has been reported 
that active metabolism and genetic instability 
under the control of oncogenic transformation 
such as over-activation of c-Myc could provide 
a platform for cancer cells to harbor an excess 
oxidative stress level (27). Moreover, previous 
studies delineated that treatment of mutant 
p53-expressing leukemic cells with different 
small molecule inhibitors could increase the 
amount of ROS level (28, 29), proposing that 
probably the absence of anti-oxidant regulatory 
protein p53 makes cells vulnerable to the 
cytotoxic effects of anti-cancer agents (30). 
Accordingly, our results clearly showed that 
abrogation of c-Myc in NB4 cells harboring 
mutant p53 not only increased the amount of 
ROS, but also increased the expression levels 
of Bad and Bax, as two potent apoptotic genes 
with a unique cross-talk with ROS. Hitherto, 
roles deviating from canonical activity of ROS 
have been demonstrated in a fair number of 
studies. It was reported that ROS production 
could provide a signal that in partnership 
with the extinguished NF-κB axis regulate 
cell cycle progression (21). Interestingly, we 
found that the decreased replication of DNA as 
well as reduced cell population in S phase was 
coupled with the suppression of NF-κB axis 
upon NB4 cells treatment with the inhibitor. 
Noteworthy, the inhibitory impact of 10058-
F4 on NF-κB network became more prominent 
where we found that the suppression of NF-κB 
using carfilzomib exerted a superior cytotoxic 
effects in NB4.
Acting as a double edged sword, induction 
of autophagy could either trigger cell death or 
induce a resistance phenotype, according to the 
cancer cell type (13, 14 and 31). Consistently, 
investigating the effects of 10058-F4, which 
as a single agent reduced the expression levels 
of autophagy-related genes, in combination 
with a well-known autophagy inhibitor 
revealed that the inhibition of autophagy not 
only resulted in a concentration-dependent 
cytotoxicity, but also exerted a superior 
cytotoxicity in inhibitors-treated NB4 cells; 
indicating that the anti-leukemic effect of 
10058-F4 was mediated, at least partly, 
through the suppression of autophagy. Playing 
in a triangle, the tight correlation between 
the autophagy system, the PI3K signaling 
pathway and c-Myc has been investigated 
in several studies. In a study conducted by 
Balakumaran et al., it has been suggested that 
activation of c-Myc in prostate cancer cells 
could on one hand activate the PI3K signaling 
pathway, and on the other hand regulated 
the activity of autophagy system (26). By 
investigating the effect of 10058-F4 on the 
PI3K pathway, we found that the amount of 
phosphorylated Akt is elevated in response to 
the inhibitor which could be probably due to 
the great desire of malignant cells for longer 
survival. Notably, our results revealed that 
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simultaneous blockade of PI3K and c-Myc 
remarkably diminished the survival capacity 
of NB4 cells, which may explain, at least 
partially, the compensatory role of the PI3K 
pathway upon 10058-F4 treatment (Figure 
8). Taken together, the present study showed 
that 10058-F4 had a significant anti-tumor 
activity against hematologic malignant cells, 
especially in APL-derived cells. In addition, 
we reported for the first time that the anti-
leukemic property of the inhibitor was exerted 
irrespective to the molecular status of p53; 
suggestive of the probable application of 
10058-F4 in both mutant and wild-type p53-
expressing leukemic cells.
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